A phase 2 trial of daratumumab monotherapy for patients with newly diagnosed cardiac stage IIIb AL amyloidosis.
文献摘要
Abstract Treatment options for patients with immunoglobulin light chain (AL) amyloidosis and advanced cardiac involvement remain limited. The prospective phase 2 European Myeloma Network 22 trial included patients with previously untreated AL amyloidosis, measurable hematologic disease, and Mayo2004/European cardiac stage IIIB disease to receive daratumumab monotherapy at the standard dose and schedule for up to 2 years (28-day cycles); patients with inadequate response after 3 cycles could additionally receive weekly bortezomib and dexamethasone. The primary end point was 6-month overall survival (OS) rate. Of 40 patients enrolled, 10 (25.0%) received additional treatment with bortezomib and dexamethasone. The 6-month OS rate was 65% (95% confidence interval, 48.2-77.6), and median OS was 10.4 months. The best hematologic response rate (partial response or better) up to 6 months was 75% (very good partial response or better, 47.5%; complete response, 12.5%), with the median time to first and best hematologic response being 1 week and 2.3 months, respectively. Cardiac response rate at 6 months was 30%. Common serious adverse events were cardiac failure (25%), sudden cardiac death (10%), and acute kidney injury (7.5%). The patients' quality of life remained stable throughout the trial treatment and observation. In patients with high-risk, advanced (stage IIIB) AL amyloidosis, daratumumab monotherapy was feasible and well tolerated, achieving rapid hematologic responses and associated with prolonged survival relative to historical cohorts. Cardiac response rates at 6 months were significant, considering advanced cardiac disease. These findings support daratumumab as the backbone of anticlonal therapy in advanced cardiac AL amyloidosis. This trial was registered at www.clinicaltrials.gov as #NCT04131309.